MGNX News and Press, MacroGenics Inc. From 11/14/22

On a generally uninspiring day for the market, biotech MacroGenics (NASDAQ: MGNX) was a standout performer. The company's share price gained nearly 4% in value against a slumping S&P 500 index, on a new and quite bullish take from an analyst. That analyst was BMO Capital...

Not to jinx it, but MacroGenics (NASDAQ: MGNX) might just be at the start of a winning streak. For the second straight day, powered by very encouraging quarterly results, the biotech's shares saw a notable rise on Monday. The stock gained more than 8% on the day as yet another analy...

Now this is how a stock finishes the trading week in style. On Friday, commercial-stage biotech MacroGenics (NASDAQ: MGNX) surged 22% higher. That was thanks to its latest earnings report, which was greeted very warmly by investors. For its third quarter, MacroGenics earned ...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2022 Earnings Call Nov 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2022 Earnings Call Transcript

MacroGenics press release ( NASDAQ: MGNX ): Q3 GAAP EPS of -$0.40 beats by $0.04 . Revenue of $41.73M (+166.5% Y/Y) beats by $12.45M . Cash, cash equivalents and marketable securities as of September 30, 2022, were $123.6 million, compared to $243.6 millio...

Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end Anticipated update on lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecul...

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its fin...

– Gilead Granted Exclusive Option to License MGD024, a Phase 1 CD123×CD3 DART ® Molecule with Potential to Treat Various Hematologic Malignancies – – Potential for Companies to Collaborate on Two Additional Future Research Programs ...

Summary MacroGenics shut down a trial and reduced its workforce. The B7-H3 program seems to be in a lot of trouble. I will avoid this stock. Since my February coverage, MacroGenics ( MGNX ) is down 64%. The company has a drug called margetuximab approved in patie...

MacroGenics (NASDAQ: MGNX) investors were suffering from a case of the Mondays, as their stock lost more than 8% of its value on the day. That compared rather unfavorably to the more than 1% gain of the S&P 500 index. MacroGenics' decline came about because of a fresh price ...